While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) employ immunosuppressive regimens used in heart transplants, the precise ...
Zacks Investment Research on MSN
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know
Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century ...
XCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
StemEdit encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical ...
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Subscribe to Platinum Performance as of 11/29/24. Get access to powerful investment ...
) has been revised to $4.08 / share. This is a decrease of 20.00% from the prior estimate of $5.10 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results